Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Inoviq Ltd ( (AU:IIQ) ) has shared an announcement.
INOVIQ has reported positive in vivo proof-of-concept data for its EGFR-targeted CAR-NK exosome therapy in a triple-negative breast cancer mouse model, with its CAR-NK-EVs delivering a 61.5% tumour reduction over 28 days, 100% survival in treated mice, and a favourable safety profile compared with controls. The study also showed improved precision targeting with reduced non-specific liver accumulation, validating the company’s EXO-ACE manufacturing platform and underpinning a newly filed provisional patent on CAR-targeting and exosome purification, which strengthens INOVIQ’s intellectual property position and supports the advancement of its off-the-shelf, cell-free immunotherapy platform for hard-to-treat solid tumours.
The most recent analyst rating on (AU:IIQ) stock is a Sell with a A$0.50 price target. To see the full list of analyst forecasts on Inoviq Ltd stock, see the AU:IIQ Stock Forecast page.
More about Inoviq Ltd
INOVIQ Ltd is an ASX-listed exosome technology company focused on next-generation cancer diagnostics and therapeutics. Its portfolio spans commercial-stage exosome isolation products, clinical-stage ovarian and breast cancer diagnostics, and a preclinical chimeric antigen receptor (CAR) exosome therapeutic program targeting solid tumours, including triple-negative breast cancer.
Average Trading Volume: 190,234
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$47.16M
See more insights into IIQ stock on TipRanks’ Stock Analysis page.